newheader.jpg
 


Conference Menu

Overview
Agenda-Day One
Agenda-Day Two
Download PDF
Register
Poster
Hotel & Travel
Press Pass
Request Brochure
Order CD
Send to a Colleague
Upcoming Conferences

Corporate Support:

 

Lead
Sponsoring Publication:

 

Sponsoring Publications:

 
Web Partners:
 

Held immediately prior to the 3rd Annual Biodefense August 18-19, 2004

DAY 1


Sunday, August 15


4-6pm Early Registration


Monday, August 16


7:00 Registration, Poster and Exhibit Set-up, and Coffee
 

Keynote Session 

8:30 Chairperson's Opening Remarks
Dr. Mauro Ferrari, Professor of Biomedical Engineering, and Associate Vice President for Health Sciences, Technology, and Commercialization, The Ohio State University 

8:45 Opportunities for Nanotechnology for Cancer - and Beyond
Mauro Ferrari, Ph.D., Edgar Hendrickson Professor of Biomedical Engineering, Professor of Internal Medicine, Division of Oncology, Associate Vice President, Health Sciences Technology and Commercialization, The Ohio State University, and President, the International Society for BioMEMS and Biomedical Nanotechnology 
From early detection to the treatment of advanced disease and the control of symptoms, micro/nanotechnology offer exceptional opportunities for breakthough advances in the fight against cancer. By their very nature of platform technologies, it may well be expected that the resulting approaches will translate into beneficial opportunities for other pathologies, as well. In this talk, I will examine five of my personal favorite candidates for high-impact areas for medical nanotech: Synthetic replicas of lesion microenvironment for in-vitro analysis and testing; Nanotechs for the shortening of clinical trials and regulatory pathways; Nanotechs for early detection via biofluid analysis; Cell-based cancer therapeutic and enhanced in-vivo diagnostics; and Architectural, multiscale, biofouling-indifferent biosensors.

9:15 Role of Nanotechnology in Early Cancer Detection and Treatment
Ellen G. Feigal, M.D., Acting Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute 

9:45 Micro and Nanoscale Platforms for Targeted Therapeutics
Dr. Tejal A. Desai, Associate Professor, Department of Biomedical Engineering, Boston University 
Micro and nanofabrication techniques which permit the creation of therapeutic delivery systems that possess a combination of structural, mechanical, and perhaps electronic features may surmount challenges associated with conventional delivery of therapy. In this presentation, micro and nanoscale devices capable of performing therapeutic functions in vivo are discussed, with emphasis on engineering devices to interact specifically with the biological interface. 

10:15 Systems Design and Nanodevices
Dr. Stephen C. Lee, Associate Professor, Biomedical Engineering Center, Chemical Engineering, Cellular and Molecular Biochemistry, The Ohio State University

10:45 Coffee Break with Exhibit and Poster Viewing


Drug Delivery Systems


11:15 Chairperson's Remarks

11:20 Polymer Microchip for Biodegradable Drug Delivery
Prof. Michael J. Cima, Department of Materials Science and Engineering, Massachusetts Institute of Technology, Grace Y. Kim, Massachusetts Institute of Technology, and Prof. Robert S. Langer, Department of Chemical Engineering, Massachusetts Institute of Technology
A drug's efficacy is highly dependent on the manner in which it is administered, as well as the dose amount and schedule. Conventional drug delivery, such as oral tablets or injection, introduces an initial high concentration of drug that decreases rapidly. However, some therapies, such as a chemotherapy or vaccine delivery, require pulses of drugs or a combination of drugs over months. A biodegradable polymer device containing multiple drug reservoirs may provide the flexibility to deliver drugs in such a manner. Furthermore, the small size of the device allows local delivery of therapeutic agents, reducing drug doses and side effects. 

11:50 Advances in Drug Delivery
Dr. Rolfe C. Anderson, Director New Technology Development, Biomedical Engineering, ALZA Corporation 
Drug concentration within a target tissue, and its variation over time, can control efficacy and toxicity. Much of drug-development focuses on achieving a desirable concentration-time profile. Chemical- and device-approaches to drug delivery are being used to augment conventional pharmaceutical development and by providing greater control of dynamic drug concentration. ALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. As new compounds emerge from biotechnology and genetic research, ALZA technologies continue to evolve, providing unique delivery platforms that extend the potential of important new therapies.

12:20 Lunch on your own

1:30 Magneto/Optical Nanoparticles 
Dr. Lee Josephson, Assistant Professor, Chemistry, Harvard University
Nanoparticles that exhibit both superparamagnetism and near infrared fluorescence (NIRF) can be used to detect the expression of molecules by flow cytometry, fluorescence microscopy or small animal optical imaging. Their multimodal design permits pre-operative MRI and intra-operative NIRF based imaging, a unique capability that can be exploited in neurosurgical applications. Magneto/Optical Nanoparticles are non-toxic and have a wide range of uses in research and medicine. 

2:00 Use of a Nanopore Membrane in a Novel Drug Delivery Device
Dr. Phyllis Gardner, Associate Professor of Medicine, Stanford University School of Medicine
Many peptide and protein drugs are currently self-administered by means of frequent subcutaneous injections over extended periods of time. By means of an implantable titanium drug delivery device (NanoGATE) that uses silicon nanopore membrane to control the release (by diffusion) of an encapsulated drug at a nearly constant rate, one achieves nearly zero order drug kinetics over long durations of time. Thus one avoids the poor pharmacokinetics associated with injections, providing an optimized delivery route for these compounds. The drug can be formulated as a dry powder or concentrated suspension, maintaining drug stability. The drug is protected from the body's immunological response by the nanopore membrane, which not only controls release but excludes unwanted cells and proteins. 

2:30 Panel Discussion with the Speakers

3:00 Refreshment Break, Exhibit and Poster Viewing


Nanoparticles for Molecular Imaging


3:30 Chairperson's Remarks
Daniel C. Sullivan M.D., Associate Director, Cancer Imaging Program, National Cancer Institute

3:35 Nanoparticles for Molecular Imaging
Dr. Bruce Johnson, GE Global Research Center

4:05 Clinical Opportunities and Challenges for Imaging with Nanoparticles
Dr. Michael V. Knopp, Professor of Radiology, Novartis Chair and Director of Imaging Research, Department of Radiology, The Ohio State University 
Rapid translation of nanoparticle applications into clinical in vivo uses require sensitive in vivo detection and frequently spatial localization. In addition to radiolabeled methodologies, Magnetic Resonance Imaging (MRI) has an inherent high sensitivity and is a very capable methodology. An overview of current imaging methodologies, their sensitivities and challenges as they relate to clinical opportunities will be presented. Imaging is quite capable of non-invasive detection of in vivo accumulation, retention and elimination of nanoparticles.

4:35 Multifunctional Nanosystems for Molecular Imaging and Targeted Therapeutics in Vivo
Dr. Samuel A. Wickline, Professor of Medicine, Biomedical Engineering, and Physics, and Co-director, Cardiology, Washington University 
The next generation of pharmaceutical agents will be targeted against specific molecular pathways and/or locales within the body. Our laboratory is engaged in a multidisciplinary effort to develop systemically deliverable ligand-targeted nanoparticles for noninvasive in vivo image-based detection of picomolar quantities of pathological epitopes that are the sources of cancer and cardiovascular disease. We have devised strategies for delivering drugs or genes to those sites with the use of targeted nanoparticle carriers that can incorporate various classes of ligands (e.g., antibodies, small molecules) and selected drugs active against cancer and atherosclerosis and thrombosis. These particles also can be imaged in vivo with MRI, nuclear, CT, or ultrasound methods based on incorporation of payloads of gadolinium chelates, radionuclides, iodinated compounds, or perfluorocarbon content respectively. Drugs such as doxorubicin, taxol, fumagillan can be incorporated and delivered selectively to individual cells of choice through a patent-pending process of "contact facilitated drug delivery," which is proving to dramatically enhance tumor lysis and plaque regression. 

5:05 Water Soluble Quantum Dots for Fluorescence Imaging in Vivo
Dr. Marcel Bruchez, Principal Staff Scientist, Quantum Dot Corporation
Semiconductor quantum dots (nanocrystals) are a fluorescent material with striking brightness and photstability properties that enable unprecedented fluorescence based detection. The optical characteristics of our Qdot(R) Conjugates enable observation of cellular phenotype, migration of cells through tissues, and provide tools that allow the observation of complex behavior in living systems with simple fluorescence detection. Applications of Qdot conjugates in large and small animals for vascular imaging, lymphatic mapping, and molecular imaging and pathology will be discussed.

5:35 Panel Discussion with the Speakers

6:00 Networking Reception with Poster and Exhibit Viewing

7:15 Close of Day One


Call for Sponsors and Exhibitors
Showcase your company's expertise, brand your solutions and develop revenue opportunities with qualified decision-makers by becoming an Exhibitor or Sponsor of BioMEMS and NANOtech World 2004! Contract exhibit booth space by June 15, 2004 and you will save $300! If you want to discuss sponsoring or exhibiting at BioMEMS and NANOtech 2004, please contact
Angela Parsons at 781-972-5467 or aparsons@healthtech.com

foot.jpg


Cambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Cambridge Health Associates | Discovery On Target |
Health-IT World
| Bio-IT World Conference & Expo  | Molecular Medicine Tri-Conference | PEGS| PepTalk | Pharma DD
World Pharmaceutical Congress |

Your  Life Science Network

Cambridge Healthtech Institute  |  250 First Avenue  |  Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425
chi@healthtech.com